Company intelligence / Profile preview

Jinxin Fertility

Ownership: Private
Employees: ~3198
Development stage: Other

Overview

Jinxin Fertility is the third-largest provider of IVF services in China by market share. The company operates a network of hospitals and clinics offering a full spectrum of fertility-related healthcare services. It has expanded into obstetrics, gynecology, pediatrics, and molecular genetics services. In 2022 it reported revenue growth to RMB2.364 billion (~$331 million USD), with net income affected by COVID but still positive[2][3]. The company continues to expand its service offerings and geographic reach[1][3].

Therapeutic areas: Women's HealthOther
Modalities: Assisted reproductive technology (ART)In vitro fertilization (IVF)
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Jinxin Fertility.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinxin Fertility.

Explore the full profile